rss-es – Página 118

Teligent Pharma, Inc.’s Issues Voluntary Recall of Lidocaine HCl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due to Super Potency

Murilo Freitas - 16:15, 2 de septiembre de 2021474

Teligent Pharma, Inc. is voluntarily recalling one lot of Lidocaine HCl Topical Solution 4%, 50ml in a screw cap glass bottle to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-m

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teligent-pharma-incs-issues-voluntary-recall-lidocaine-hcl-topical-solution-4-lot-14218-exp-092022

rss rss-es rss-pt

FDA In Brief: FDA Reaches Milestone in Competitive Generic Therapy Drug Approvals

Murilo Freitas - 15:14, 1 de septiembre de 2021404

FDA In Brief: FDA Reaches Milestone in Competitive Generic Therapy Drug Approvals
http://www.fda.gov/news-events/press-announcements/fda-brief-fda-reaches-milestone-competitive-generic-therapy-drug-approvals

rss rss-es rss-pt

Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare® Test Kits

Murilo Freitas - 04:00, 1 de septiembre de 2021523

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. (“Magellan”), expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead T

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/magellan-diagnostics-inc-expands-voluntary-recall-leadcarer-test-kits

rss rss-es rss-pt

Quercetin with Vitamin C/Quercetin 15x (2021-09-02)

Murilo Freitas - 04:00, 1 de septiembre de 2021407

Quercetin with Vitamin C/Quercetin 15x (2021-09-02)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76377r-eng.php

rss rss-es rss-pt

Eco-Med Prevent Hand Sanitizer (2021-09-02)

Murilo Freitas - 04:00, 1 de septiembre de 2021439

Eco-Med Prevent Hand Sanitizer (2021-09-02)
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76383r-eng.php

rss rss-es rss-pt

FDA In Brief: FDA to Hold Advisory Committee Meeting to Discuss Pfizer-BioNTech’s Application for COVID-19 Booster

Murilo Freitas - 20:54, 31 de agosto de 2021396

FDA In Brief: FDA to Hold Advisory Committee Meeting to Discuss Pfizer-BioNTech’s Application for COVID-19 Booster
http://www.fda.gov/news-events/press-announcements/fda-brief-fda-hold-advisory-committee-meeting-discuss-pfizer-biontechs-application-covid-19-booster

rss rss-es rss-pt

Entidades nos invitan a escuchar y actuar en comunidad para prevenir el comportamiento suicida

Murilo Freitas - 16:02, 31 de agosto de 2021431

Entidades nos invitan a escuchar y actuar en comunidad para prevenir el comportamiento suicida

01 de setiembre del 2021. San José. Con el objetivo de sensibilizar a la población, abordar los estigmas y mitos que acompañan al comportamiento suicida...

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2166-entidades-nos-invitan-a-escuchar-y-actuar-en-comunidad-para-prevenir-el-comportamiento-suicida

rss rss-es rss-pt

Janus Kinase (JAK) inhibitors: Drug Safety Communication – FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death

Murilo Freitas - 04:00, 31 de agosto de 2021479

FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.

http://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk

rss rss-es rss-pt